A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia

Brief description of study

The purpose of this study is to determine the safety, tolerability, and efficacy of the study drug, olezarsen. Apolipoprotein C-III (apoC-III) is a protein found in blood that increases triglyceride levels. The study drug, olezarsen (ISIS 678354), is designed to reduce the amount of apoC-III in the blood. This may help lower the risk of developing pancreatitis and to improve other symptoms of severe hypertriglyceridemia.

Clinical Study Identifier: s22-01605

ClinicalTrials.gov Identifier: NCT05552326

Principal Investigator: Cindy L Bredefeld.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies